AtriCure (NASDAQ:ATRC – Free Report) had its target price decreased by JPMorgan Chase & Co. from $51.00 to $46.00 in a ...

AtriCure (NASDAQ:ATRC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a research note issued to investors on Thursday,Benzinga reports.

AtriCure (ATRC) delivered earnings and revenue surprises of 46.67% and 0.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Canaccord lowered the firm’s price target on AtriCure (ATRC) to $52 from $66 and keeps a Buy rating on the shares. The firm updated its model ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC – Research Report) and Journey ...

Investors might want to bet on AtriCure (ATRC), as it has been recently upgraded ... which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating ...

Karen Prange, a director at $ATRC, sold 6,100 shares of the company on 03-05-2025 for an estimated $232,531. We received data on the trade from a recent SEC filing ...